Table A12.6Sustained Disability Progression Results Between Base Case Model and Adjusted Models Using Covariates

TreatmentBase CaseCovariate: Baseline
EDSS
Covariate: Time
Since Symptom
Onset
Covariate: Treatment
Duration
Covariate: Mean
Relapses
95% CrI95% CrI95% CrI95% CrI95% CrI
Alemtuzumab 12 mg0.56(0.32, 0.87)0.56(0.32, 0.86)0.56(0.32, 0.86)0.56(0.32, 0.86)0.50(0.27, 0.81)
Alemtuzumab 24 mg0.49(0.2, 0.97)0.49(0.2, 0.96)0.49(0.2, 0.96)0.49(0.2, 0.96)0.44(0.17, 0.91)
Dimethyl fumarate 240 mg0.73(0.53, 0.97)0.73(0.53, 0.97)0.73(0.53, 0.97)0.73(0.53, 0.97)0.74(0.54, 0.98)
Fingolimod 0.5 mg0.76(0.52, 1.04)0.76(0.52, 1.04)0.76(0.52, 1.04)0.76(0.52, 1.04)0.76(0.52, 1.03)
Glatiramer acetate 20 mg0.83(0.65, 1.02)0.83(0.65, 1.02)0.83(0.65, 1.02)0.83(0.65, 1.02)0.86(0.67, 1.07)
Interferon beta-1a 30 mcg0.87(0.67, 1.09)0.87(0.67, 1.09)0.87(0.67, 1.09)0.87(0.67, 1.09)0.86(0.67, 1.08)
Interferon beta-1a 60 mcg0.86(0.51, 1.27)0.87(0.51, 1.27)0.87(0.51, 1.27)0.87(0.51, 1.27)0.86(0.51, 1.26)
Interferon beta-1a 22 mcg0.89(0.58, 1.23)0.89(0.58, 1.23)0.89(0.58, 1.23)0.89(0.58, 1.23)0.85(0.55, 1.2)
Interferon beta-1a 44 mcg0.84(0.61, 1.08)0.84(0.61, 1.08)0.84(0.61, 1.08)0.84(0.61, 1.08)0.76(0.53, 1.04)
Interferon beta-1b 250 mcg0.74(0.5, 0.97)0.74(0.5, 0.97)0.74(0.5, 0.97)0.74(0.5, 0.97)0.76(0.52, 0.99)
Natalizumab 300 mg0.67(0.4, 1.01)0.67(0.41, 1.01)0.67(0.41, 1.01)0.67(0.41, 1.01)0.67(0.41, 1)
Teriflunomide 7 mg0.85(0.54, 1.19)0.85(0.54, 1.19)0.85(0.54, 1.19)0.85(0.54, 1.19)0.85(0.54, 1.19)
Teriflunomide 14 mg0.80(0.5, 1.15)0.80(0.5, 1.15)0.80(0.5, 1.15)0.80(0.5, 1.15)0.80(0.5, 1.14)

CrI = credible interval; EDSS = Expanded Disability Status Scale; mcg = microgram; mg = milligram.

From: APPENDIX 12, SUMMARY OF RESULTS FROM SUBGROUP ANALYSES

Cover of Management of Relapsing-Remitting Multiple Sclerosis
Management of Relapsing-Remitting Multiple Sclerosis [Internet].
CADTH Therapeutic Review, No. 1.2.
Copyright © CADTH March 2013.

You are permitted to make copies of this document for non-commercial purposes provided it is not modified when reproduced and appropriate credit is given to CADTH. You may not otherwise copy, modify, translate, post on a website, store electronically, republish or redistribute any material from the website in any form or by any means without the prior written permission of CADTH.

Please contact CADTH’s Vice-President of Corporate Services at ac.htdac@secivresetaroproc with any inquiries about this notice or other legal matters relating to CADTH’s services.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.